Citations

Clear

299 citation(s) found for "Solomon, B".

TERT gene harbors multiple variants associated with pancreatic cancer susceptibility
Campa, Daniele , Rizzato, Cosmeri , Pacetti, Paola, Vodička, Pavel , Cleary, Sean P. , Capurso, Gabriele , Bueno‐de‐Mesquita, H. Bas, Werner, Jens , Butterbach, Katja, Ivanauskas, Audrius , Giese, Nathalia A. , Petersen, Gloria M. , Fogar, Paola, Bassi, Claudio , Ryska, Miroslav , Theodoropoulos, George , Li, Donghui , Greenhalf, William , Pasquali, Claudio , Hackert, Thilo , Fuchs, Charles S. , Mohelníková-Duchoňová, Beatrice , Funel, Niccola , Dieffenbach, Aida Karina, Buring, Julie E. , Holcátová, Ivana , Costello, Eithne , Zambon, Carlo‐Federico , Kupčinskas, Juozas , Bracci, Paige M. , Pezzilli, Raffaele , Olson, Sara H. , Sesso, Howard D. , Hartge, Patricia, Strobel, Oliver , Małecka‐Panas, Ewa , Visvanathan, Kala , Arslan, Alan A. , Pedrazzoli, Sergio , Souček, Pavel , Gioffreda, Domenica , Talar‐Wojnarowska, Renata , Scarpa, Aldo , Mambrini, Andrea , Jacobs, Eric J. , Jamroziak, Krzysztof , Tavano, Francesca , Bambi, Franco , Landi, Stefano , Austin, Melissa A. , Vodičková, Ludmila, Brenner, Hermann , Fave, Gianfranco Delle, Piepoli, Ada, Cantore, Maurizio , Zheng, Wei , Wolpin, Brian M. , Ámundadóttir, Laufey T. , Canzian, Federico , Wang, Zhaoming , Salvia, Roberto , Stolzenberg‐Solomon, Rachael Z. , Gazouli, Maria , Wang, Zhaoming , Kooperberg, Charles , Sperti, Cosimo , Wareham, Nicholas J. , Kupcinskas, Juozas , Risch, Harvey A. , Kraft, Peter , Key, Tim , Klein, Alison P. , Chanock, Stephen Jacob , Amundadottir, Laufey , Arslan, Alan A , Canzian, Federico , Wang, Zhaoming , Visvanathan, Kala , Brenner, Hermann , Strobel, Oliver , Zheng, Wei , Cleary, Sean P , Vodicka, Pavel , Landi, Stefano , Holcatova, Ivana , Tavano, Francesca

Mayo Clinic

International Journal of Cancer | May 5, 2015 | Volume: 137 | Issue: 9 | Pages: 2175-2183

10.1002/ijc.29590 | PMID 25940397 Get It

A small number of common susceptibility loci have been identified for pancreatic cancer, one of which is marked by rs401681 in the TERT–CLPTM1L gene region on chromosome 5p15.33. Because this region is characterized by low linkage disequilibrium, we sought to identify whether additional single nucleotide polymorphisms (SNPs) could be related to pancreatic cancer risk, independently of rs401681. We performed an in‐depth analysis of genetic variability of the telomerase reverse transcriptase (TERT) and the telomerase RNA component (TERC) genes, in 5,550 subjects with pancreatic cancer and 7,585 controls from the PANcreatic Disease ReseArch (PANDoRA) and the PanScan consortia. We identified a significant association between a variant in TERT and pancreatic cancer risk (rs2853677, odds ratio = 0.85; 95% confidence interval = 0.80–0.90, p = 8.3 × 10−8). Additional analysis adjusting rs2853677 for rs401681 indicated that the two SNPs are independently associated with pancreatic cancer risk, as suggested by the low linkage disequilibrium between them (r2 = 0.07, D′ = 0.28). Three additional SNPs in TERT reached statistical significance after correction for multiple testing: rs2736100 (p = 3.0 × 10−5), rs4583925 (p = 4.0 × 10−5) and rs2735948 (p = 5.0 × 10−5). In conclusion, we confirmed that the TERT locus is associated with pancreatic cancer risk, possibly through several independent variants.
Abstract LB-289: A phase I dose escalation study of TKM-080301, a RNAi therapeutic directed against PLK1, in patients with advanced solid tumors.
Ramanathan, Ramesh K., Hamburg, Solomon I. , Seetharam, ­Mahesh , Kundranda, Madappa N. , Fredlund, Paul, Gilbert, M. Jean , Mast, C.A. van der, Semple, Sean C., Judge, Adam D., Crowell, Brynne, Vocila, Linda, MacLachlan, Ian , Northfelt, Donald W. , Borad, Mitesh J. , Lee, Peter P.

Mayo Clinic

Cancer Research | August 14, 2014 | Volume: 73 | Issue: 8_Supplement | Pages: LB-289-LB-289

10.1158/1538-7445.am2013-lb-289 Get It

Abstract Background: Polo-like kinase 1 (PLK1) is a serine/threonine kinase that regulates multiple critical aspects of cell progression. PLK1 is over-expressed in many human tumor types and its over-expression is a negative prognostic indicator of patient outcome in a variety of cancers. TKM-080301 is a lipid nanoparticle formulation of a small interfering RNA (siRNA) directed against PLK1 that has been shown to effect highly selective reductions in PLK1 mRNA in vitro and in tumor xenograft models in mice. Methods: A phase I multi-center, open-label, non-randomized, dose-escalation study of TKM-080301 is ongoing in patients with advanced solid tumors or lymphoma. Sequential cohorts of 3 to 6 patients receive TKM-080301 as a 30-minute IV infusion on Days 1, 8, and 15 of a 28-day cycle. Primary objectives include determination of safety, maximum tolerated dose (MTD) and dose limiting toxicities (DLTs). Secondary objectives include characterization of pharmacokinetics (PK) and preliminary assessment of anti-tumor activity and pharmacodynamic effects. Pre-and post-dose biopsy samples are being collected from patients treated after DLT has been established. Results: Twenty-three (23) patients, receiving a cumulative total of 128 doses, have been treated with TKM-080301 at doses ranging from 0.15 to 0.9 mg/kg/week. The most common drug-related adverse events have been mild-to-moderate infusion related reactions with delayed onset, pyrexia, chills, nausea, vomiting, and fatigue. Mild, transient increases in certain cytokines (e.g., IL-6, IL-8, MCP-1) have been observed at dose levels ≤0.75 mg/kg/week and generally correlated with the timing of delayed infusion reactions. DLTs were observed at 0.9 mg/kg/week and included hypoxia/dyspnea in one patient (with a previous history of asthma) and thrombocytopenia in another patient. The dose level was subsequently reduced to 0.75 mg/kg/week. Pharmacokinetic parameters determined after the first dose in Cycles 1 and 2 demonstrated dose proportional Cmax and AUC and no obvious accumulation. Two patients have received TKM-080301 for at least 6 months (6 cycles) with no evidence of cumulative toxicity, including one patient with stable disease (colon) and one patient with a durable confirmed partial response (carcinoid tumor) who has received 8+ cycles of treatment. Conclusions: Preliminary results from this first-in-human trial indicate TKM-080301 was generally well-tolerated by the majority of patients. Preliminary antitumor efficacy has been observed, supporting PLK1 as a therapeutic target. As two DLTs were observed at the dose of 0.9 mg/kg/week, patient accrual is continuing at the 0.75 mg/kg/week dose level. Citation Format: Ramesh K. Ramanathan, Solomon I. Hamburg, Mitesh J. Borad, Mahesh Seetharam, Madappa N. Kundranda, Peter Lee, Paul Fredlund, Mark Gilbert, Cathy Mast, Sean C. Semple, Adam D. Judge, Brynne Crowell, Linda Vocila, Ian MacLachlan, Donald W. Northfelt. A phase I dose escalation study of TKM-080301, a RNAi therapeutic directed against PLK1, in patients with advanced solid tumors. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr LB-289. doi:10.1158/1538-7445.AM2013-LB-289
Proficiency of nerve conduction using standard methods and reference values (cl. NPhys Trial 4)
Litchy, William J. , Albers, James W., Wolfe, James, Bolton, Charles F., WALSH, NANCY, Klein, Christopher J. , Zafft, Andrew J., Russell, James W. , Zwirlein, Melanie, Overland, Carol J., Davies, Jenny L., Carter, Rickey E. , Dyck, P. James B. , Investigators, the CI. Nphys Trial 4, Tesfaye, Solomon , Investigators, the CI. Nphys Trial 4, Klein, Christopher J , Carter, Rickey E

Mayo Clinic

Muscle & Nerve | March 19, 2014 | Volume: 50 | Issue: 6 | Pages: 900-908

10.1002/mus.24243 | PMID 24644133 Get It

ABSTRACTIntroductionThe Cl. NPhys Trial 3 showed that attributes of nerve conduction (NC) were without significant intraobserver differences, although there were significant interobserver differences. Methods: Trial 4 tested whether use of written instructions and pretrial agreement on techniques and use of standard reference values, diagnostic percentile values, or broader categorization of abnormality could reduce significant interobserver disagreement and improve agreement among clinical neurophysiologists. Results: The Trial 4 modifications markedly decreased, but did not eliminate, significant interobserver differences of measured attributes of NC. Use of standard reference values and defined percentile values of abnormality decreased interobserver disagreement and improved agreement of judgment of abnormality among evaluators. Therefore, the same clinical neurophysiologist should perform repeat NCs of therapeutic trial patients. Conclusions: Differences in interobserver judgment of abnormality decrease with use of common standard reference values and a defined percentile level of abnormality, providing a rationale for their use in therapeutic trials and medical practice. Muscle Nerve 50: 900–908, 2014
Variants Associated with Susceptibility to Pancreatic Cancer and Melanoma Do Not Reciprocally Affect Risk
Wu, Lang , Yang, Xiaohong R. , Rabe, Kari G. , Arslan, Alan A. , Canzian, Federico , Wolpin, Brian M. , Ámundadóttir, Laufey T. , Petersen, Gloria M. , Goldstein, Alisa M, Yang, Xiaohong Rose, Stolzenberg-Solomon, Rachael, Goldstein, Alisa M. , Yu, Herbert , Stolzenberg‐Solomon, Rachael Z. , Chaffee, Kari G. , Amundadottir, Laufey , Arslan, Alan A , Canzian, Federico

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | March 19, 2014 | Volume: 23 | Issue: 6 | Pages: 1121-1124

10.1158/1055-9965.epi-13-0627 | PMID 24642353 Get It

Abstract Background: Melanoma cases may exist in pancreatic cancer kindreds, whereas there is increased risk of pancreatic cancer in familial melanoma. The two cancers may share genetic susceptibility variants in common. Methods: Three dbGaP (datasets in Genotypes and Phenotypes)-deposited GWAS (genome-wide association study) datasets (MD Anderson melanoma, PanScan 1, and PanScan 2 for pancreatic cancer) were used. Thirty-seven melanoma susceptibility variants in 22 genomic regions from published GWAS, plus melanoma-related genes and pathways were examined for pancreatic cancer risk in the PanScan datasets. Conversely, nine known pancreatic cancer susceptibility variants were examined for melanoma risk in the MD Anderson dataset. Results: In the PanScan data, initial associations were found with melanoma susceptibility variants in NCOA6 [rs4911442; OR, 1.32; 95% confidence interval (CI), 1.03–1.70; P = 0.03], YWHAZP5 (rs17119461; OR, 2.62; 95% CI, 1.08–6.35; P = 0.03), and YWHAZP5 (rs17119490; OR, 2.62; 95% CI, 1.08–6.34; P = 0.03), TYRP1 (P = 0.04), and IFNA13 (P = 0.04). In the melanoma dataset, two pancreatic cancer susceptibility variants were associated: NR5A2 (rs12029406; OR, 1.39; 95% CI, 1.01–1.92; P = 0.04) and CLPTM1L-TERT (rs401681; OR, 1.16; 95% CI, 1.01–1.34; P = 0.04). None of these associations remained significant after correcting for multiple comparisons. Conclusion: Reported variants of melanoma genes and pathways do not play a role in pancreatic cancer predisposition. Reciprocally, pancreatic cancer susceptibility variants are not associated with melanoma risk. Impact: Known melanoma-related genes and pathways, as well as GWAS-derived susceptibility variants of melanoma and pancreatic cancer, do not explain the shared genetic etiology of these two cancers. Cancer Epidemiol Biomarkers Prev; 23(6); 1121–4. ©2014 AACR.
The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction
Greene, Stephen J. , Gheorghiade, Mihai , Pieske, Burkert , Burnett, John C. , Roessig, Lothar, Stasch, Johannes‐Peter, Solomon, Scott D. , Paulus, Walter J. , Borlaug, Barry A. , Vaduganathan, Muthiah , Solomon, Scott David , Butler, Javed

Mayo Clinic

Journal of the American Heart Association | December 12, 2013 | Volume: 2 | Issue: 6 | Pages: No page available

10.1161/jaha.113.000536 | PMID 24334823 Get It

Fatty acids found in dairy, protein and unsaturated fatty acids are associated with risk of pancreatic cancer in a case-control study
Jansen, Rick J. , Robinson, Dennis P. , Frank, Ryan D. , Anderson, Kristin E. , Bamlet, William R. , Oberg, Ann L. , Rabe, Kari G. , Petersen, Gloria M. , Olson, Janet E. , Sinha, Rashmi R. , Stolzenberg‐Solomon, Rachael Z. , Chaffee, Kari G. , Bamlet, William R , Jansen, Rick J

Mayo Clinic

International Journal of Cancer | October 29, 2013 | Volume: 134 | Issue: 8 | Pages: 1935-1946

10.1002/ijc.28525 | PMID 24590454 Get It

Multicenter trial of the proficiency of smart quantitative sensation tests
Dyck, P. James B. , Argyros, Barbara, Russell, James W. , Gahnstrom, Linde E., Nalepa, Susan, Albers, James W., Lodermeier, Karen A., Zafft, Andrew J., Klein, Christopher J. , Litchy, William J. , Davies, Jenny L., Carter, Rickey E. , Melton, L. Joseph , (Appendix), members of the Cl versus NPhys Trials, Tesfaye, Solomon , (Appendix), members of the Cl versus NPhys Trials, Klein, Christopher J , Carter, Rickey E

Mayo Clinic

Muscle & Nerve | August 8, 2013 | Volume: 49 | Issue: 5 | Pages: 645-653

10.1002/mus.23982 | PMID 23929701 Get It

ABSTRACTIntroduction: We assessed proficiency (accuracy and intra‐ and intertest reproducibility) of smart quantitative sensation tests (smart QSTs) in subjects without and with diabetic sensorimotor polyneuropathy (DSPN). Methods: Technologists from 3 medical centers using different but identical QSTs independently assessed 6 modalities of sensation of the foot (or leg) twice in patients without (n = 6) and with (n = 6) DSPN using smart computer assisted QSTs. Results: Low rates of test abnormalities were observed in health and high rates in DSPN. Very high intraclass correlations were obtained between continuous measures of QSTs and neuropathy signs, symptoms, or nerve conductions (NCs). No significant intra‐ or intertest differences were observed. Conclusions: These results provide proof of concept that smart QSTs provide accurate assessment of sensation loss without intra‐ or intertest differences useful for multicenter trials. Smart technology makes possible efficient testing of body surface area sensation loss in symmetric length‐dependent sensorimotor polyneuropathies. Muscle Nerve 49: 645–653, 2014
Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes
Collaborative, The Beyond TME, Antoniou, Anthony , Beynon, John, Bhangu, Aneel , Bose, Pradeep, Boyle, Kirsten, Branagan, Graham , Burling, David , Chang, George J. , Clark, Susan K. , Colquhoun, Patrick, Crane, Christopher H. , Darzi, Ara , Das, Prajnan , Delaney, Conor P. , Desai, Anant, Davies, Mark, Dozois, Eric J. , Fitzgerald, J.E.F. , Frizelle, Frank , George, Bruce , George, Mark, Georgiou, Panagiotis , Gupta, Arun , Harris, Dean , Hawkins, M. , Holm, Torbjörn, Hompes, Roel , Jeys, Lee , Jenkins, John T. , Kiran, Ravi P. , Koh, Cherry , Laurberg, Søren , Law, Wai Lun, Liberman, A. Sender , McArthur, D. Ray, Mirnezami, Alex H. , Moran, Brendan , Mortenson, Neil, Myers, Eddie, Nicholls, R. John, O’Connell, P. R. , O’Dwyer, Sarah , Oliver, Alex, Pallan, Arvind, Patel, Prashant , Patel, Uday , Radley, Simon, Ramsey, Kelvin , Rasmussen, P., Richard, Carole, Rutten, H.J.T. , Sagar, P. M. , Sebag‐Montefiore, David , Stocchi, Luca , Swallow, Carol J. , Tait, Diana , Tan, Emile , Tekkis, Paris, As, Nicholas van , Vuong, T. , Wiggers, Theo , Wilson, Malcolm , Winter, Desmond C. , Woodhouse, Christopher, Collaborative, The Beyond TME, Ali, Simak , Brown, Gina , Wilt, Johannes H.W. de , Desai, Anant , Dietz, David , Duff, Michael J. B. , Dziki, Adam Janusz , Glynne‐Jones, Rob , Goldin, Robert , Harji, Deena Pravin , Heriot, Alexander G. , Marshall, Michelle Berger , Radley, Simon, Solomon, Michael J. , Jeys, Lee M

Mayo Clinic

British Journal of Surgery | June 21, 2013 | Volume: 100 | Issue: 8 | Pages: E1-E33

10.1002/bjs.9192_1 | PMID 23901427 Get It

Consensus abstract Background The management of primary rectal cancer beyond total mesorectal excision planes (PRC-bTME) and recurrent rectal cancer (RRC) is challenging. There is global variation in standards and no guidelines exist. To achieve cure most patients require extended, multivisceral, exenterative surgery, beyond conventional total mesorectal excision planes. The aim of the Beyond TME Group was to achieve consensus on the definitions and principles of management, and to identify areas of research priority. Methods Delphi methodology was used to achieve consensus. The Group consisted of invited experts from surgery, radiology, oncology and pathology. The process included two international dedicated discussion conferences, formal feedback, three rounds of editing and two rounds of anonymized web-based voting. Consensus was achieved with more than 80 per cent agreement; less than 80 per cent agreement indicated low consensus. During conferences held in September 2011 and March 2012, open discussion took place on areas in which there is a low level of consensus. Results The final consensus document included 51 voted statements, making recommendations on ten key areas of PRC-bTME and RRC. Consensus agreement was achieved on the recommendations of 49 statements, with 34 achieving consensus in over 95 per cent. The lowest level of consensus obtained was 76 per cent. There was clear identification of the need for referral to a specialist multidisciplinary team for diagnosis, assessment and further management. Conclusion The consensus process has provided guidance for the management of patients with PRC-bTME or RRC, taking into account global variations in surgical techniques and technology. It has further identified areas of research priority.
Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes
Collaborative, The Beyond TME, Antoniou, Anthony , Beynon, John, Bose, Pradeep, Boyle, Kirsten, Branagan, Graham , Brown, Gina , Burling, David , Chang, George J. , Clark, Susan K. , Colquhoun, Patrick, Crane, Christopher H. , Darzi, Ara , Das, Prajnan , Wilt, Johannes H. W. de, Delaney, Conor P. , Desai, Anant, Davies, Mark, Dozois, Eric J. , Fitzgerald, J.E.F. , Frizelle, Frank , George, Bruce , George, Mark, Georgiou, Panagiotis , Glynne‐Jones, R., Goldin, Robert , Gupta, Arun , Harris, Dean , Hawkins, M. , Holm, Torbjörn, Jenkins, John T. , Kiran, Ravi P. , Laurberg, Søren , Law, Wai Lun, Liberman, A. Sender , McArthur, D. Ray, Mirnezami, Alex H. , Moran, Brendan , Mortenson, Neil, Myers, Eddie, Nicholls, R. John, O’Connell, P. R. , O’Dwyer, Sarah , Oliver, Alex, Pallan, Arvind, Patel, Prashant , Radley, Simon, Ramsey, Kelvin , Rasmussen, P., Richard, Carole, Rutten, H.J.T. , Sagar, P. M. , Sebag‐Montefiore, David , Solomon, Michael J. , Stocchi, Luca , Swallow, Carol J. , Tait, Diana , Tekkis, Paris, As, Nicholas van , Vuong, T. , Wiggers, Theo , Wilson, Malcolm , Winter, Desmond C. , Woodhouse, Christopher, Coombes, R. Charles , Collaborative, The Beyond TME, Ali, Simak , Bhangu, Aneel , Desai, Anant , Dietz, David , Duff, Michael J. B. , Dziki, Adam Janusz , Harji, Deena Pravin , Heriot, Alexander G. , Hompes, Roel , Jeys, Lee , Koh, Cherry , Marshall, Michelle Berger , Patel, Uday , Radley, Simon, Tan, Emile , Solomon, Michael J

Mayo Clinic

British Journal of Surgery | June 10, 2013 | Volume: 100 | Issue: 8 | Pages: 1009-1014

10.1002/bjs.9192 | PMID 23754654 Get It

Consensus abstract Background The management of primary rectal cancer beyond total mesorectal excision planes (PRC-bTME) and recurrent rectal cancer (RRC) is challenging. There is global variation in standards and no guidelines exist. To achieve cure most patients require extended, multivisceral, exenterative surgery, beyond conventional total mesorectal excision planes. The aim of the Beyond TME Group was to achieve consensus on the definitions and principles of management, and to identify areas of research priority. Methods Delphi methodology was used to achieve consensus. The Group consisted of invited experts from surgery, radiology, oncology and pathology. The process included two international dedicated discussion conferences, formal feedback, three rounds of editing and two rounds of anonymized web-based voting. Consensus was achieved with more than 80 per cent agreement; less than 80 per cent agreement indicated low consensus. During conferences held in September 2011 and March 2012, open discussion took place on areas in which there is a low level of consensus. Results The final consensus document included 51 voted statements, making recommendations on ten key areas of PRC-bTME and RRC. Consensus agreement was achieved on the recommendations of 49 statements, with 34 achieving consensus in over 95 per cent. The lowest level of consensus obtained was 76 per cent. There was clear identification of the need for referral to a specialist multidisciplinary team for diagnosis, assessment and further management. Conclusion The consensus process has provided guidance for the management of patients with PRC-bTME or RRC, taking into account global variations in surgical techniques and technology. It has further identified areas of research priority.
Meat-Related Mutagens and Pancreatic Cancer: Null Results from a Clinic-Based Case–Control Study
Jansen, Rick J. , Robinson, Dennis P. , Frank, Ryan D. , Bamlet, William R. , Oberg, Ann L. , Rabe, Kari G. , Petersen, Gloria M. , Anderson, Kristin E., Stolzenberg‐Solomon, Rachael Z. , Olson, Janet E. , Sinha, Rashmi R. , Chaffee, Kari G. , Bamlet, William R , Jansen, Rick J

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | May 1, 2013 | Volume: 22 | Issue: 7 | Pages: 1336-1339

10.1158/1055-9965.epi-13-0343 | PMID 23632817 Get It

Abstract Background: Pancreatic cancer is a devastating disease for which the role of dietary factors remains inconclusive. The study objective was to evaluate risk of pancreatic cancer associated with meat preparation methods and meat-related mutagen consumption using a clinic-based case–control design. Methods: There were 384 cases and 983 controls; subjects provided demographic information and completed a 144-item food frequency questionnaire, which was used to estimate meat mutagen intake using the National Cancer Institute's CHARRED database (Bethesda, MD). Logistic regression was used to calculate ORs and 95% confidence intervals (CI), adjusted for factors including age, sex, cigarette smoking, body mass index, and diabetes mellitus. Results: Overall, the findings were null with respect to meat mutagen intake and pancreatic cancer. Conclusions: The results do not support an association between well-done meat or meat-related mutagen intake and pancreatic cancer and contrast with generally increased risks reported in previous studies. Impact: These data contribute to evidence about pancreatic cancer and potentially carcinogenic compounds in meat. Cancer Epidemiol Biomarkers Prev; 22(7); 1336–9. ©2013 AACR.